Tested Applications
| Positive WB detected in | U2OS cells, HeLa cells, HepG2 cells, LNCaP cells, Jurkat cells, A549 cells, MCF-7 cells, MOLT-4 cells, NK-92 cells, Raji cells |
| Positive IF/ICC detected in | HepG2 cells |
| Positive FC (Intra) detected in | Jurkat cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:5000-1:50000 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:50-1:500 |
| Flow Cytometry (FC) (INTRA) | FC (INTRA) : 0.40 ug per 10^6 cells in a 100 µl suspension |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
67476-1-Ig targets MGMT in WB, IHC, IF/ICC, FC (Intra), ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Cited Reactivity | human, mouse |
| Host / Isotype | Mouse / IgG2a |
| Class | Monoclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag29936 Product name: Recombinant human MGMT protein Source: e coli.-derived, PET28a Tag: 6*His Domain: 1-207 aa of BC000824 Sequence: MDKDCEMKRTTLDSPLGKLELSGCEQGLHEIKLLGKGTSAADAVEVPAPAAVLGGPEPLMQCTAWLNAYFHQPEAIEEFPVPALHHPVFQQESFTRQVLWKLLKVVKFGEVISYQQLAALAGNPKAARAVGGAMRGNPVPILIPCHRVVCSSGAVGNYSGGLAVKEWLLAHEGHRLGKPGLGGSSGLAGAWLKGAGATSGSPPAGRN Predict reactive species |
| Full Name | O-6-methylguanine-DNA methyltransferase |
| Calculated Molecular Weight | 22 kDa |
| Observed Molecular Weight | 22 kDa |
| GenBank Accession Number | BC000824 |
| Gene Symbol | MGMT |
| Gene ID (NCBI) | 4255 |
| RRID | AB_2882703 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Protein A purification |
| UNIPROT ID | P16455 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
MGMT is the primary vehicle for cellular removal of alkyl lesions from the O-6 position of guanine and the O-4 position of thymine. While key to the maintenance of genomic integrity, MGMT also removes damage induced by alkylating chemotherapies, inhibiting the efficacy of cancer treatment [PMID:23065697].MGMT is the primary mechanism for the removal of alkylation damage from the O-6 position of guanine [PMID: 17482892]. The O-6 position of guanine is one of several positions in DNA bases to which alkyl groups are attached in SN1 alkylation reactions, and this repair has been well-characterized in mammalian cells and via MGMT homologs in bacteria and Archaea.[PMID: 10767620]
Protocols
| Product Specific Protocols | |
|---|---|
| FC protocol for MGMT antibody 67476-1-Ig | Download protocol |
| IF protocol for MGMT antibody 67476-1-Ig | Download protocol |
| WB protocol for MGMT antibody 67476-1-Ig | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
The MGMT Monoclonal antibody (1H2C9), catalog number 67476-1-Ig, has 5 total citations. These appear in Cancer Discovery, Nature Communications, Nucleic Acids Research, Journal of Colloid and Interface Science, and Scientific Reports. The associated research fields include glioblastoma immunotherapy, DNA repair (PARthanosis), transcript error biology, RNAi-mediated cancer sensitization, and temozolomide resistance mechanisms.
| Species | Application | Title |
|---|---|---|
Cancer Discov Targeting Microglial Metabolic Rewiring Synergizes with Immune Checkpoint Blockade Therapy for Glioblastoma | ||
Nucleic Acids Res KDM6B promotes PARthanatos via suppression of O6-methylguanine DNA methyltransferase repair and sustained checkpoint response. | ||
J Colloid Interface Sci Brain-targeted polymersomes mediating RNAi of STAT3 sensitize glioblastoma to temozolomide and immunotherapy | ||
Sci Rep MGMT upregulation mediates Temozolomide resistance conferred USP5 dependency.
|
